Upstream Processing

Jan 01, 2008
BioPharm International
By BioPharm International Editors
Design space concepts are key to a successful technology transfer.
Jan 01, 2008
BioPharm International
By BioPharm International Editors
Chinese hamster ovary (CHO) cells are used extensively in the biopharmaceutical industry to produce recombinant proteins that require post-translation modification for full biological functionality. Optimization of culture conditions for recombinant CHO cell lines presents challenges in light of the diverse nutritional requirements observed with different clonally derived cell lines.
Nov 01, 2007
BioPharm International
An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.
Oct 09, 2007
BioPharm International
By BioPharm International Editors
SAFC (St. Louis, MO), a member of the Sigma-Aldrich Group, has announced a $29-million investment to significantly expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel
Oct 01, 2007
BioPharm International
Multivariate data analysis can help biotech manufacturers deepen their process understanding.
Oct 01, 2007
BioPharm International
In one series of experiments, the glycosylation site of IgG1 was removed and an IgA glycosylation site was introduced—resulting in a total loss of biological function.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It became a strategic imperative to find a better, more efficient way to manufacture our products. To continue with the status quo was untenable.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It is commonly believed that technologies in the next 10–15 years will enable sequencing an individualized human genome for less than $1,000. With innovations like these, the twenty-first century will certainly belong to biotechnology. From an industrial standpoint, the discovery of therapeutic molecules and the development of cell lines and processes to produce these molecules will be of paramount importance. This article describes various approaches that have been prevalent in the industry or are likely to be used in the future for generating cell lines with desirable traits and developing high titer cell culture processes.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
Favrille, a San Diego-based biopharmaceutical company, is one of a handful of firms on the forefront of personalized medicine. Because personalized treatment is tailored to an individual's biology, it has the potential to be far more effective than current approaches to disease management.
Oct 01, 2007
BioPharm International
Regulatory agencies have evolved along with the biotechnology industry to define quality standards.
native1_300x100
lorem ipsum